Condition
Ebola Virus Infection
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02363322Phase 1CompletedPrimary
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
NCT02319772Phase 1Completed
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
NCT02041715Phase 1TerminatedPrimary
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
NCT01518881Phase 1TerminatedPrimary
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
Showing all 4 trials